← Eichor
Condition: Antibody Drug Conjugates Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Antibody Drug Conjugates

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
Phase 1 · 15 location(s) · OnCusp Therapeutics, Inc. · NCT06234423Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018A Phase I Clinical Study to Evaluate the Safety, Tolerability, and PK of HLX48 in Advanced/Metastatic Solid Tumors
Phase 1 · 7 location(s) · Shanghai Henlius Biotech · NCT07473726A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · MediLink Therapeutics (Suzhou) Co., Ltd. · NCT07197827Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer:
Phase N/A · 1 location(s) · Fundación Pública Andaluza para la Investigación Biomédica A · NCT07582887A Study of EBC-129 in Advanced Solid Tumours
Phase 1 · 5 location(s) · EDDC (Experimental Drug Development Centre), A*STAR Research · NCT05701527A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
Phase 1 · 1 location(s) · Akeso · NCT06929663A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
Phase 1 · 6 location(s) · Janssen Research & Development, LLC · NCT07082920A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06041516Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT06649331Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastati
Phase 2 · 27 location(s) · National Cancer Institute (NCI) · NCT06311214A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Benefi
Phase 1/Phase 2 · 68 location(s) · BioNTech SE · NCT07111520Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or
Phase 3 · 88 location(s) · Daiichi Sankyo · NCT05950945Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic H
Phase 1 · 91 location(s) · AstraZeneca · NCT04686305A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/Phase 2 · 14 location(s) · Salubris Biotherapeutics Inc · NCT06667960Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Biohaven Therapeutics Ltd. · NCT06384807A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
Phase 3 · 232 location(s) · Daiichi Sankyo · NCT06203210A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 83 location(s) · AstraZeneca · NCT07098338A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612176Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Phase 1/Phase 2 · 4 location(s) · Zhejiang ACEA Pharmaceutical Co. Ltd. · NCT05565807A Study of MRG006A in the Treatment of Patients With Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Lepu Biopharma Co., Ltd. · NCT07093970A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1 · 38 location(s) · CStone Pharmaceuticals · NCT05279300HS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Phase 2 · 28 location(s) · Hansoh BioMedical R&D Company · NCT06014190ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Phase 1 · 12 location(s) · Adcendo ApS · NCT06597721ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer
Phase 1 · 1 location(s) · Hansoh BioMedical R&D Company · NCT06825624Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian
Phase 1 · 9 location(s) · AstraZeneca · NCT07402915
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.